Welcome to our dedicated page for Abcam Plc news (Ticker: ABCM), a resource for investors and traders seeking the latest updates and insights on Abcam Plc stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Abcam Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Abcam Plc's position in the market.
On November 3, 2020, Abcam plc announced the publication of its Annual Report for the year ending June 30, 2020. The report is now available on the company's website. Shareholders can access the report and the Notice of Annual General Meeting either electronically or via paper communications. Additionally, Abcam will release its first dedicated Impact Report on November 9, 2020, focusing on its commitment to sustainability and creating positive impacts in life sciences. The company serves around 750,000 researchers globally, with a mission to advance biological understanding.
Abcam plc (AIM: ABC, Nasdaq: ABCM) has announced it will retain its existing Long-Term Incentive Plan (LTIP) metrics and targets as approved by shareholders in 2018. This decision follows consultations with shareholders regarding the Group’s overall LTIP structure and performance framework. Additionally, Abcam plans to engage with shareholders in the upcoming months to develop a new Remuneration Policy for future approval.
Abcam plc has completed an offering of 10,287,000 American Depositary Shares (ADSs) at $17.50 each, raising approximately $180.0 million. This offering includes 1,341,782 ADSs from underwriters’ options and is part of a registered public offering in the U.S. The ADSs began trading on NASDAQ under the symbol 'ABCM' on October 22, 2020. Following the offering, the company's total issued share capital is now 226,551,853 ordinary shares. This event reflects Abcam's ongoing strategy to strengthen its financial position in the life sciences sector.
Abcam announced the pricing of an offering of 8,945,218 American Depositary Shares (ADSs) at $17.50 per ADS, raising approximately $156.5 million before expenses. The ADSs will trade under the symbol ABCM on NASDAQ, starting October 22, 2020. A 30-day option for underwriters to purchase an additional 1,341,782 ADSs is included. Closing is anticipated on October 26, 2020. The offering is a registered public offering in the U.S. and is subject to customary closing conditions. Forward-looking statements caution potential risks affecting the offering.